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Abstract: Poly(ADP-Ribose) polymerases (PARPs) are enzymes that metabolize NAD+. PARP1
and PARP10 were previously implicated in the regulation of autophagy. Here we showed that
cytosolic electron-dense particles appear in the cytoplasm of C2C12 myoblasts in which PARP2 is
silenced by shRNA. The cytosolic electron-dense bodies resemble autophagic vesicles and, in line with
that, we observed an increased number of LC3-positive and Lysotracker-stained vesicles. Silencing
of PARP2 did not influence the maximal number of LC3-positive vesicles seen upon chloroquine
treatment or serum starvation, suggesting that the absence of PARP2 inhibits autophagic breakdown.
Silencing of PARP2 inhibited the activity of AMP-activated kinase (AMPK) and the mammalian
target of rapamycin complex 2 (mTORC2). Treatment of PARP2-silenced C2C12 cells with AICAR,
an AMPK activator, nicotinamide-riboside (an NAD+ precursor), or EX-527 (a SIRT1 inhibitor)
decreased the number of LC3-positive vesicles cells to similar levels as in control (scPARP2) cells,
suggesting that these pathways inhibit autophagic flux upon PARP2 silencing. We observed a similar
increase in the number of LC3 vesicles in primary PARP2 knockout murine embryonic fibroblasts.
We provided evidence that the enzymatic activity of PARP2 is important in regulating autophagy.
Finally, we showed that the silencing of PARP2 induces myoblast differentiation. Taken together,
PARP2 is a positive regulator of autophagic breakdown in mammalian transformed cells and its
absence blocks the progression of autophagy.
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1. Introduction
Poly(ADP-ribose) (PAR) metabolism is an evolutionarily conserved posttranslational modification
of proteins [1]. PAR is a branched polymer of ADP-ribose derived from NAD+ by its enzymatic
cleavage. PAR is synthesized by members of the Poly(ADP-Ribose) polymerase enzyme family,
among them, PARP1 and PARP2 [2]. PARP2 can be activated by binding to DNA or RNA through
its N-terminus or through signaling pathways [2–4]. When activated, PARP2 accounts for 15–20% of
total cellular PARP activity [5,6]. Both enzymes are involved in a plethora of cellular processes, among
these, in the regulation of cellular energy and metabolic homeostasis [1,7–9].
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Autophagy is a process in cells that is dedicated to the removal of damaged cellular proteins and
components (e.g., mitochondria) [10,11]. The process is well-conserved across evolution. Damaged
cellular components are engulfed by a biomembrane that is pickled with LC3 protein that is an accepted
biomarker of autophagy [12]. The resulting autophagosomes then fuse with and are degraded in acidic
lysosomes, a process that can be inhibited by chloroquine, an acidification inhibitor that prolongs the
half-life of LC3-positive vesicles [12]. Autophagic flux is tightly linked to the bioenergetic output of
cells through energy sensors, such as AMP-activated kinase (AMPK), mechanistic target of rapamycin
(mTOR), PARPs, and SIRT1 [13–15]. The dysregulation of autophagy has a pathogenic role in disorders,
such as cancer or metabolic diseases [10,11].
PARP10 [16] and PARP1 [17] were shown to be involved in the regulation of autophagy. PARP1
may act as a pro-autophagy factor [17–25], where its activation promotes autophagy under numerous
conditions that are associated with DNA damage (DNA intercalators, irradiation, oxidative stress,
heavy metal intoxication, ultraviolet B (UVB) radiation, etc.) [17–19,26–30]. In line with that, genetic
silencing or pharmacological inhibition of PARP1 suppressed autophagy [17–19]. In our current study
we showed an opposite impact of PARP2 on autophagy as compared to PARP1.
2. Material and Methods
2.1. Chemicals
All chemicals were from Sigma-Aldrich (St. Louis, MO, USA) unless stated otherwise. The source
of key chemicals are listed in Table 1.
Table 1. The source of key chemicals used in the study.
Chemical Company Catalog Number Concentration Length of Treatment
chloroquine Sigma-Aldrich C6628 25 µM 2 h
AICAR Santa Cruz BT sc-200659A 1 mM 24 h
rapamycin Cayman Chemical 13346 20 nM 24 h
olaparib Selleckchem S1060 1 µM 24 h
NR ChromaDex - 500 µM 24 h
resveratrol Sigma-Aldrich R5010 50 µM 24 h
EX-527 Selleckchem S1541 25 µM 24 h
PJ34 Sigma-Aldrich P4365 3 µM 24 h
AICAR—5-Aminoimidazole-4-carboxamide ribonucleotide, NR—nicotinamide-riboside.
2.2. Cell Culture
PARP2-silenced C2C12 cells were described in [31]. C2C12 cells are of murine origin. C2C12
cells were maintained in DMEM (Sigma-Aldrich, 4500 mg/L glucose) containing 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin, and 2 mM l-glutamine at 37 ◦C with 5% CO2. In C2C12 cells,
PARP2 was silenced by specific shRNA (the sequence was tested in [32]) that was maintained over
extended periods (the cell line was created in 2010) by selection under 2.5 µg/mL for C2C12 cells [31].
Cells containing the control, non-specific sequence are termed scPARP2, while those containing the
PARP2-specific shRNA are termed shPARP2 cells. Cells were differentiated in DMEM (Sigma-Aldrich,
1000 mg/L glucose) containing 2% horse serum for 4 days.
Male primary murine embryonic fibroblasts (MEFs) were created in the frame of a previous
study [32]. Cells were maintained in DMEM (Sigma-Aldrich, 4500 mg/L glucose) containing 20% FBS,
1% penicillin/streptomycin, and 2 mM l-glutamine at 37 ◦C with 5% CO2.
2.3. Transient Transfection
Silencer select siRNAs were obtained from Thermo Fisher Scientific (Walthman, MA, USA).
siRNAs targeting PARP2 (cat. no. 4390771, ID: s62056 as #1, s62057 as #2), SIRT1 (cat. no. 4390771, ID:
s96766), and negative control (cat. no. 4390843) were used. Cells were seeded into a 24-well plate and
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transfected with siRNA at a final concentration of 30 nM using Lipofectamine RNAiMax (Invitrogen,
Carlsbad, CA, USA) transfection reagent. Cells were incubated for 48 h.
2.4. Immunofluorescence and Confocal Microscopy
Cells were seeded on glass coverslips, washed with PBS, fixed with 4% paraformaldehyde for
10 min at 37 ◦C, and permeabilized with 1% Triton X-100 in PBS for 10 min. Between each steps,
cells were rinsed three times with PBS. Cells were blocked with 1% bovine serum albumin (BSA) in PBS
for 1 h at room temperature. For cellular localization of LC3 protein, cells were incubated with LC3A/B
conjugated with Alexa Fluor 488 antibody diluted in blocking buffer overnight at 4 ◦C. Differentiated
C2C12 cells were incubated with Texas Red X-Phalloidin (1:150, Invitrogen, Carlsbad, CA, USA) for
1 h. Cell nuclei were visualized with DAPI (NucBlue Fixed Cell ReadyProbes Reagent, Invitrogen).
Confocal images were acquired with Leica TCS SP8 confocal microscope (Leica, Wetzlar, Germany)
and LAS X 3.5.5.19976 software (Leica, Wetzlar, Germany). Nonspecific binding of the secondary
antibodies was checked in control experiments (not shown).
2.5. LysoTracker Deep Red Staining
Cells were grown on glass coverslips, washed with PBS, and stained with LysoTracker Deep Red
(Thermo Fisher Scientific, Walthman, MA, USA) using a working concentration of 100 nM for 30 min
and fixed in 4% paraformaldehyde for 10 min at 37 ◦C.
Confocal images were acquired with Leica TCS SP8 confocal microscope and LAS X
3.5.5.19976 software.
2.6. SDS-PAGE and Western Blotting
Cells were washed with PBS and lysed in lysis buffer (50 mM Tris, pH 8, 150 mM NaCl, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1 mM
PMSF, protease inhibitor cocktail) on ice and boiled with 5x SDS sample buffer (310 mM Tris-HCl,
pH 6.8, 50% glycerol, 10% SDS, 100 mM DTT, 0.01% bromophenol blue) and 2-mercaptoethanol.
Protein extracts were separated by SDS polyacrylamide gels and transferred onto nitrocellulose
membranes. Membranes were blocked with 5% BSA in TBSTween for 1 h at room temperature and
incubated with primary antibodies overnight at 4 ◦C. Membranes were probed with the respective
peroxidase-conjugated secondary antibody. Signals were visualized by enhanced chemiluminescence
reaction and captured by ChemiDoc Touch Imaging System (Bio-Rad, Hercules, CA, USA). Bands
were quantified by densitometry using ImageJ software [33] and densitometry data were analyzed by
statistical methods. Antibodies used in this study are shown in Table 2.
Table 2. Antibodies used in the study.
Antibody Company Dilution
LC3A/B Alexa Fluor 488 Conjugate Cell Signaling Technology, 13082 1:50
LC3A/B Cell Signaling Technology, 12741 1:1000
PARP2 Enzo Life Sciences,ALX-210-899-R100 1:2000
SIRT1 EMD Millipore, 07-131 1:1000
AMPKα Cell Signaling Technology, 5832 1:1000
Phospho-AMPKα (Thr172) Cell Signaling Technology, 2535 1:1000
p70 S6 Kinase Sigma-Aldrich, SAB4502691 1:1000
Phospho-p70 S6 Kinase (Thr389) Cell Signaling Technology, 9205 1:1000
Akt Cell Signaling Technology, 9272 1:1000
Phospho-Akt (Ser473) Cell Signaling Technology, 4060 1:1000
Poly(ADP-ribose) Enzo Life Sciences,BML-SA216-0100 1:1000
Anti-mouse IgG, HRP-linked Sigma-Aldrich, A9044 1:2000
Anti-rabbit IgG, HRP-linked Cell Signaling Technology, 7074 1:2000
Anti-β-actin-Peroxidase Sigma-Aldrich, A3854 1:20,000
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2.7. Total RNA Preparation, Reverse Transcription-coupled quantitative PCR (RT-qPCR)
Total RNA was prepared using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. Then, 2 µg of total RNA was used for reverse transcription using
a high-capacity cDNA reverse transcription kit (Applied Biosystem, Foster City, CA, USA). Diluted
cDNA was used for qPCR reaction. Primers are listed in Table 3. Expression was normalized to the
geometric mean of murine 34B4 and cyclophilin.
Table 3. Primers used in the study.
Gene Name Forward Primer Reverse Primer
Myf5 GACACAGCTTCCCTCTCTCCAG ACGTATTCTGCCCAGCTTGTCT
MyoD1 GCTTTGAGAGATCGACTGCAGC TGTCCTTTCTTTGGGGCTGGAT
Mef2a CTCCCCGTGATAGAATGACCCC GGTCACTGCCATCATAGGAGCT
Mef2d GTGTTTACAAGGGATCAGCGCC AGAGCTCCAAATGTGAAGCCCT
Mef2c ACGATTCAGTAGGTCACAGCCC CTGTTATGGCTGGACACTGGGA
cyclophilin TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT
36B4 AGATTCGGGATATGCTGTTGG AAAGCCTGGAAGAAGGAGGTC
2.8. Electron Microscopy (EM)
Cell samples were processed for electron microscopic investigation similarly to [34]. Cells were
fixed in 3% glutaraldehyde dissolved in 0.1 M cacodylate buffer (pH 7.4) containing 5% sucrose for 6 h
at room temperature. After washing in 0.1 M cacodylate buffer (pH 7.4), cells were post-fixed in 1%
osmium tetroxide dissolved in 0.1 M cacodylate buffer (pH 7.4) for 1 h. Then, cells were dehydrated
with a graded ethanol series. Samples were embedded into DurcupanACM resin (Sigma-Aldrich).
Ultrathin sections were cut with Leica Ultracut UCT Ultramicrotome, collected on Formvar-coated
single-slot grids, and counterstained using uranyl acetate and Reynolds lead citrate. Sections were
examined with a JEOL 1010 transmission electron microscope (JEOL Ltd., Akishima, Tokyo, Japan)
and photographed with an Olympus Veleta CCD camera (Olympus, Sinjuku, Tokyo, Japan).
Morphometric assessment was accomplished using the ImageJ software. EM pictures of at least
45 different cells of each group were analyzed and cytosolic electron-dense particles were counted.
2.9. Statistical Analysis
LC3 or LysoTracker-positive vesicles were counted using ImageJ software. All numerical data
are presented as the average ± SEM unless otherwise stated. For numerical values, significance
between groups was analyzed by paired, two-tailed Student’s t-test. For multiple comparisons we
used a one-way ANOVA test followed by Dunnett’s honestly significance (HSD) or Tukey’s post
hoc test, as indicated in figure captions. The n number in the figure legends denotes the number of
biological replicates.
3. Results
3.1. Silencing of PARP2 Induces Autophagy in C2C12 Cells
As the model system, we chose C2C12 cells in which PARP2 was silenced (shPARP2) and their
isogenic control line (scPARP) was transfected with control (non-specific) shRNA sequence [31,32]
(Figure 1). These cells were subjected to electron microscopy analysis. We were surprised to find
cytosolic electron-dense particles exclusively in the shPARP2 C2C12 cells (Figure 2) that looked like
late-stage autophagic vesicles (that is, autophagosomes that underwent fusion with late endosomes or
lysosomes, with cytoplasmic cargo still recognizable in their lumen).
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To provide evidence that these vesicles were indeed of autophagic nature, we determined LC3 
levels in scPARP2 and shPARP2 cells. LC3 levels were induced in the shPARP2 cells compared to the 
scPARP2 controls (Figure 3A), with a striking increase in the level of lipidated, autophagic 
membrane-associated LC3-II. Since the scPARP/shPARP2 C2C12 cell line pair was established years 
earlier, we performed transient silencing with siRNA molecules. Both PARP2-specific siRNA 
molecules efficiently reduced the expression of PARP2 and increased the level of lipidated LC3-II 
(Figure 3B). Finally, we assessed LC3 expression and distribution in immunofluorescence (IF) 
experiments that showed similar results to Western blotting: a striking increase in the number of 
strongly LC3-positive vesicles were found in PARP2-silenced cells compared to the respective 
controls (Figure 3C). As an alternative to LC3 staining, we charged scPARP2 and shPARP2 cells with 
LysoTracker that stains acidic vesicles, i.e., autolysosomes. Using LysoTracker we also observed a 
marked induction of punctate staining in the shPARP2 cell population (Figure 4). 
Figure 1. Validation of PARP2 silencing in stably-transfected C2C12 cells. PARP2 expression was
assessed in scPARP2 and shPARP2 cells by Western blotting (n = 3). *** represents statistically significant
differences between the scPARP2 and shPARP2 cells at p < 0.001.
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Figure 2. Cytosolic electron-dense particles appear in PARP2-silenced cells. scPARP2 and shPARP2
C2C12 cells were analyzed by electron microscopy (n = 1, counted cells: 50/50). Red arrows and
the insert picture show the cytosolic electron-dense particles in shPARP2 cells, which were absent
in scPARP2 cells. Cytosolic electron-dense particles were counted in cells and data was plotted.
*** represents statistically significant differences between the scPARP2 and shPARP2 cells at p < 0.001.
Average ± SD is plotted. As cytosolic electron-dense bodies wer absent in the scPARP2 cells, the value
for the chart is 0 with no standard deviation.
To provide evidenc that thes ve i l er i of autophagic natur , w determined LC3
leve s in scPARP2 and s 2 cells. LC3 evels were induced in the shPARP2 cells compared
to the scPARP2 controls (Figure 3A), with a striki g increase in the level of lipi ated, autophagic
membrane-associated LC3-II. Since the scPARP/shPARP2 C2C12 cell line pair was established years
earlier, we performed transient silencing with siRNA molecules. Both PARP2-specific siRNA molecules
efficiently reduced the expression of PARP2 and increased the level of lipidated LC3-II (Figure 3B).
Finally, we assessed LC3 expression and distribution in immunofluorescence (IF) experiments that
showed similar results to W stern blotting: a striking increase in the number of strongly LC3-positive
vesicles were fo nd in P RP2-silenced cells compared to the respective co trols (Figur 3C). As an
alternative to LC3 staini g, we harged scPARP2 and shPARP2 cells with LysoTracker that stains cidic
vesicles, i.e., a tolys somes. U ing LysoTracker we also observed a ma ked induction of punctate
staining in the shPARP2 cell population (Figure 4).
We next assessed how the two cell lines respond to known modulators of autophagy, chloroquine
(blocks the clearance of autophagic vesicles by neutralizing lysosomes) and serum starvation (increases
the formation of autophagic vesicles). Both interventions led to an increased punctate LC3 signal,
which was comparable in both cell lines (Figure 5). These data suggest that, while both cell lines
respond to starvation by increased formation of autophagic vesicles, basal autophagic flux is partially
impaired in PARP2 loss-of-function cells based on similar LC3 vesicle numbers seen in the two cell
lines upon treatment with the autophagic degradation inhibitor chloroquine.
Cells 2020, 9, 380 6 of 21Cells 2019, 8, x 6 of 24 
 
 
Figure 3. Silencing of PAPR2 increases the level of LC3. (A) In scPARP2 and shPARP2 C2C12 cells, 
LC3 expression was analyzed by Western blotting (n = 3). (B) PARP2 was transiently silenced in 
C2C12 cells using two different siRNAs (n = 3). Cells were transfected with siRNAs for 48 h, then 
PARP2 and LC3 levels were determined by Western blotting. (C) LC3+DAPI immunofluorescence 
was performed in scPARP2 and shPARP2 C2C12 and in C2C12 cells where PARP2 was transiently 
silenced (n = 3). Alexa Fluor 488-linked LC3 specific antibody was used and the nuclei were visualized 
using DAPI and vesicles were counted. Representative images are presented in the figure. *, **, and 
Figure 3. Silencing of PAPR2 increases the level of LC3. (A) In scPARP2 and shPARP2 C2C12 cells, LC3
expression was analyzed by Western blotting (n = 3). (B) PARP2 was transiently silenced in C2C12 cells
using two different siRNAs (n = 3). Cells were transfected with siRNAs for 48 h, then PARP2 and LC3
levels were determined by Western blotting. (C) LC3+DAPI immunofluorescence was performed in
scPARP2 and shPARP2 C2C12 and in C2C12 cells where PARP2 was transiently silenced (n = 3). Alexa
Fluor 488-linked LC3 spe ific antibody was used and the nuclei were visualized using DAPI and vesicles
were counted. Representative images are presented in the figure. *, **, and *** represent statistically
significant differences between the indicated groups at p < 0.05, p < 0.01 and, p < 0.001, respectively.
For the determination, ANOVA test was used followed by Dunnett’s post hoc test. NEG–Negative
control, where cells were transfected with non-specific control siRNA.
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Figure 5. Chloroquine and serum starvation induce LC3 expression in scPARP2 and shPARP2 cells
to the same extent. scPARP2 and shPARP2 C2C12 cells were treated with 25 µM chloroquine for 2 h
or serum-starved for 12 h. LC3 expression was assessed in confocal microscopy experiments. Alexa
Fluor 488-linked LC3 specific antibody was used and the nuclei were visualized using DAPI, vesicles
were counted. Representative images are presented on the figure. ## and ### represent statistically
significant differences between the control and chloroquine-treated or control and serum-starved cells
at p < 0.01 or p < 0.001, respectively. *** represent statistically significant differences between the
scPARP2 and shPARP2 cells at p < 0.001. For the determination of statistical significance ANOVA test
was used followed by Tukey’s post hoc test.
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3.2. Induction of Autophagy Depends on the Induction of SIRT1 and the Inhibition of AMPK
We assessed the function of a set of energy sensors in scPARP2 and shPARP2 cells and we
found a deregulation of cellular energy sensors. mTORC1 activity, measured through assessing
the phosphorylation of the p70 S6 kinase (Phospho-p70 S6 Kinase (Thr389)), did not change in
the shPARP2 cells (Figure 6A). In contrast, AMPK activity, marked by the auto-phosphorylation of
AMPK (Phospho-AMPKα (Thr172)), was profoundly reduced (Figure 6A). Finally, mTORC2 activity,
assessed through the phosphorylation of Akt kinase (Phospho-Akt (Ser473)), showed a mild reduction
(Figure 6A). Apparently, the silencing of PARP2 led to profound changes in cellular energy sensing.Cells 2019, 8, x 9 of 24 
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Figure 6. Inhibition of AMPK and cellular NAD+ level mod late autophagy in a PARP2-dependent
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Next, we assessed whether these changes are functional by using pharmacological modulators
of the above energy sensors. The use of AICAR, an activator of AMPK, reduced the proportions of
the high LC3 expression cells compared to the shPARP2 control cells (Figure 6B), suggesting that the
suppression of AMPK activity has a causative role in the induction of autophagy. Rapamycin, an
inhibitor of mTORC1, did not change the proportions of LC3 positivity (Figure 6B). Olaparib, a PARP
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inhibitor, in line with the previous literature [17–19], decreased baseline LC3 expression, but was
unable to prevent increases in LC3 expression in the shPARP2 cells (Figure 6B). Nicotinamide riboside
(NR) decreased LC3 expression in scPARP2 cells and prevented increases in LC3 expression in shPARP2
cells (Figure 6B).
SIRT1 activation can induce autophagy [35,36] and silencing of PARP2 was shown to induce SIRT1
expression [5,31,37]. Therefore, we assessed whether SIRT1 could be implicated in the upregulation
of autophagy. We activated SIRT1 using resveratrol [38] and inhibited its enzymatic activity using
EX-527 [39]. Resveratrol induced LC3 expression both in the scPARP2 and shPARP2 cells (Figure 7A).
EX-527 treatment did not alter LC3 expression in scPARP2 C2C12 cells, while it reduced LC3 expression
in shPARP2 C2C12 cells (Figure 7A).
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Figure 7. SIRT1 activation is a key determinant of the PARP2-mediated inhibition of autophagy.
(A) scPARP2 and shPARP2 C2C12 c lls were treated with 50 µM esveratrol or 25 µM EX-527 for
24 h (n = 3). LC3 expression was assessed by confocal microscopy. Alexa Fluor 488-linked LC3
specific antibody was used and the nuclei were visualized using DAPI an vesicles were counted.
Representative images are presented on the figure. (B,C) SIRT1 was transiently silenced in scPARP2
and shPARP2 C2C12 cells using siRNA targeting SIRT1 (n = 3). Cells were transfected with siRNA for
48 h, then LC3 expression was assessed in confocal microscopy experiments and the protein level of
SIRT1 was detected by Western blotting. Alexa Fluor 488-inked LC3 specific antibody was used and
the nuclei were visualized using DAPI. Representative images are presented in the figure. Cells were
scored as described in Materials and Methods. # and ### represent statistically significant differences
between the control and treated cells at p < 0.05 and p < 0.001, respectively. *** represent statistically
significant differences between the scPARP2 and shPARP2 cells at p < 0.001. For the determination of
statistical significance, ANOVA test was used followed by Tukey’s post hoc test.
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We also assessed if silencing of SIRT1 can phenocopy the effects of EX-527. We silenced SIRT1
transiently in C2C12 cells using siRNA (Figure 7B). siRNA silencing of SIRT1 decreased LC3 expression
in shPARP2 C2C12 cells (Figure 7C).
To complement the pharmacological approach, we treated C2C12 cells that were transiently
transfected with PARP2 siRNA with the previously identified inhibitors of PARP2-induced autophagy
(AICAR, nicotinamide-riboside, and EX-527). All agents were able to inhibit increases in LC3 expression
similar to previous observations (Figure 8).
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Figure 8. Increased autophagy upon acute PARP2 silencing. PARP2 was transiently silenced in C2C12
cells using siRNA targeting PARP2 (n = 3). Cells were transfected with siRNA for 48 h, treated with 1
mM AICAR, 500 µM nicotinamide-riboside (NR), and 25 µM EX-527 for 24 h, then LC3 expression was
assessed by confocal microscopy. Alexa Fluor 488-linked LC3 specific antibody was used and the nuclei
were vi ualized using DAPI and vesicles were count d. #, ## and ### represent statistically significant
differences between the control and treated cells at p < 0.05, p < 0.01 or p < 0.001, respectively. *, **,
and *** represent statistically significant differences between the scPARP2 and shPARP2 cells at p < 0.05,
p < 0.01, and p < 0.001, respectively. For the determination of statistical significance, ANOVA test was
used followed by Tukey’s post hoc test.
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3.3. The Number of LC3-Positive Vesicles Increase in Primary Murine Embryonic Fibroblasts Upon the Genetic
Deletion of PARP2
In C2C12 cells, the efficiency of the silencing of PARP2 was around 50%. Therefore, we assessed
primary murine embryonic fibroblasts (MEFs) derived from PARP2 knockout mice [32,40], where
PARP2 protein was completely absent. The MEFs used in the current study were from het-to-het
breeding-derived male embryos; MEFs were generated for a previous study [32]. In these cells we
assessed the number of LC3-positive vesicles. In good agreement with previous observations, the
number of LC3-positive vesicles increased in the PARP2−/− MEF cells compared to their PARP2+/+
counterparts (Figure 9).
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Figure 9. The number of LC3-positive vesicles in primary PARP2 knockout MEF cells. A total of 15,000
cells from the indicated primary MEF cells were seeded and were stained for Alexa Fluor 488-linked
LC3 specific antibody and the nuclei with DAPI. Vesicles were counted. Representative images are
presented in the figure. *** represents statistically significant differences between the PARP2+/+ and
PARP2−/− MEF cells at p < 0.001. For the determination of statistical significance, ANOVA test was
used followed by Dunnett’s post hoc test. The different numbers represent different MEF clones.
3.4. The Activity of PARP2 Plays Role in Mediating Autophagy
Subsequently, we assessed whether the activity of PARP2 could play a role in the regulation of
autophagy. PARP2 is responsible for ~10–15% of total cellular PARP activity [5,6]. We assessed total
PARP activity in cells by assessing PARylation pattern in cellular lysates (Figure 10). Chloroquine
treatment induced PARylation (similarly as in [22]) and fasting reduced PARylation [41]. Silencing
of PARP2 did not change the PARylation pattern in non-treated cells. The silencing of PARP2
reduced chloroquine-induced PARylation and antagonized fasting-induced suppression of PARylation,
which altogether suggests a role for the enzymatic activity of PARP2 in the regulation of autophagy.
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Figure 11. PARP2 enzymatic activity modulates the energy sensors involved in the regulation of
autophagy. A total of 200,000 scPARP2 and shPARP2 C2C12 cells were seeded in 6-well plates that
were treated with olaparib (olap, 1 µM) and PJ34 (3 µM) for 24 h. Cellular proteins were separated by
SDS-PAGE and were blotted and probed with the antibodies indicated on panels (A–C). Bands were
subjected to densitometry. Experiments were repeated three times; a representative blot is shown.
3.5. Silencing of PARP2 Aff cts the Differentiation of C2C12 Myobla ts
The importance of PARPs were demonstrated in decision making towards differentiation [9,45–52],
including skeletal muscle differentiation [53–56]. The knockout of PARP2 induced a conversion to
more type I and oxidative type II fibers [31]. Furthermore, autophagy was implicated in muscular
differentiation and sarcopenia [57,58], making it likely that the silencing of PARP2 may affect the
differentiation of C2C12 cells. The dramatic increase in LC3-positive vesicles was maintained in
differentiated shPARP2 C2C12 cells (Figure 12A). We assessed the morphology of the differentiated
C2C12 cells and found that the cortical actin staining was more pronounced in shPARP2 cells compared
to scPARP2 cells (Figure 12B). Finally, we assessed the expression of different myogenic differentiation
markers (Myf5, MyoD1, Mef2a, Mef2d and Mef2c) on day 4, day 5, and day 6 of differentiation.
All markers showed higher expression in the shPARP2 cells compared to scPARP2 cells (Figure 12C).
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Figure 12. Silencing of PARP2 supports myogenic differentiation. A total of 20,000 scPARP2 and
shPARP2 C2C12 cells were seeded in 24-well plates that were differentiated for 4 days then (A)
LC3-positive vesicles were assessed by immunofluorescence, (B) acti cytoskeleton was stained by
Texas Red-X Phalloidin+DAPI, and (C) the expression of set of myogenic gen s wer assessed
by RT-qPCR. On panel B 100/100 cells were scored for the structure of actin cytoskeleton as diffuse,
transient, and strong cortical staining. *** represent statistical difference between scPARP2 and shPARP2
cells at p < 0.001 on panel A. ** represent statistical difference between scPARP2 and shPARP2 cells in
terms of actin morphology at p < 0.01 on panel B. In panel C, ### represents statistically significant
differences between the scPARP2 and shPARP2 cells at p < 0.001. * and ** represent statistically
significant differences between the control and differentiated cells at p < 0.05 and p < 0.01, respectively.
For the determination of statistical significance, ANOVA test was used followed by Tukey’s post hoc
test on panels A and C, while on panel B chi square test was applied.
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4. Discussion
Herein, we showed that the genetic or pharmacological silencing of PARP2 induces the number
of autophagic vesicles in cellular models through inhibiting AMPK and inducing SIRT1 activity.
Two known treatments that increase autophagic vesicle numbers, chloroquine and serum starvation,
increased punctate LC3 signal to levels that are comparable in both cell lines. This suggests that
both cell lines respond to starvation by increased formation of autophagic vesicles and that basal
autophagic flux is partially impaired in PARP2 loss-of-function cells. It is of note that in the C2C12
cells the reduction of PARP2 expression was around 50%, which limits the applicability of our findings.
Nevertheless, we showed that the number of LC3-positive increases in PARP2 knockout MEF cells too,
validating our findings in C2C12 cells.
PARP2 was originally described as a DNA repair protein. However, recent investigations have
shed light on a strong connection between PARP2 and metabolism [4,59]. PARP2 can be activated by
irregular DNA forms [60,61] and by binding to RNA [3]. Besides these, its activity can be modulated
by posttranslational modifications, such as acetylation, PARylation [62], or by controlling its expression
by lipid biomolecules [63,64] or flavonoids [65], and through mediating its subcellular localization by
serum starvation [66]. PARP2 was linked to DNA repair [6,40], thymo- and hematopoiesis [46–48],
as well as, metabolism [67,68]. We extended the list of these functions by adding its effects on autophagy.
PARP1 and PARP10 was already implicated in the regulation of autophagy. PARP10 was shown
to interact with ubiquitin receptor p62 [16], suggesting a role for PARP10 in selective autophagy.
PARP1 activation is needed for the appropriate initiation of fasting-induced autophagy [18]. Starvation
induces DNA damage [18] and, hence, PARP1 activity [18,41], which is an initiating step for autophagy.
PARP1-mediated induction of autophagy requires the coordinated activation of AMPK [18,69–72].
In fact, PARylation and nuclear export of AMPK are necessary for the initiation of autophagy [19]. There
is also contradicting evidence, however, where PARP inhibition induced autophagy or mitophagy [73,
74]. SIRT1 activation was also shown to influence autophagy [13–15]. However, the involvement of
the PARP1-SIRT1 axis [31,41,75] is also controversial [76,77]. These controversies in the role of PARP1
suggest the involvement of PARP2 in these model systems.
We showed that PARP2 controls autophagy through rearranging the cellular energy sensor system.
The genetic inhibition of PARP2 blocked AMPK activity, while pharmacological activation of AMPK
partially blocked the PARP2-dependent induction of autophagy. These findings suggest a causative
role of AMPK inhibition in the induction of autophagy. This finding is intriguing as previous literature
described AMPK as an inductor of autophagy [18,69–72,78]. Somewhat surprisingly, we did not
observe changes in the activity of mTORC1 upon PARP2 silencing. Nevertheless, the activity of the
mTORC2 complex was downregulated. mTORC1-independent and mTORC2-dependent forms of
autophagy were already reported [79–82]. The actual molecular link between PARP2 and energy
sensors is yet unknown.
A potent NAD+ precursor molecule, nicotinamide riboside [83] was able to revert PARP-2-induced
autophagic vesicle accumulation. NAD+ availability or NR supplementation promotes autophagy in
various models [84,85]. In fact, NAD+ availability improves the elimination of damaged proteins [85].
PARP2 is an NAD+-dependent enzyme [2,5,6] and, therefore, it is likely that NR supports the activity
of PARP2 through enhancing cellular NAD+ levels. This scenario is likely as the enzymatic activity of
PARP2 is required for its DNA-repair and non-repair functions [2,44,86]. Nevertheless, it should be
stated that SIRT1 independent pathways also exist upon the ablation of PARP2 that modulate autophagy,
pathways that probably involve the activation of the above-discussed energy sensor pathways.
In line with the above, SIRT1 inhibition was the most dominant in reducing the accumulation of
autophagic vesicles in shPARP2 cells. Previous studies [5,31,37,56,64] established the molecular link
between SIRT1 and PARP2. PARP2 is a repressor of the promoter of SIRT1 and, hence, the ablation
of PARP2 induces SIRT1 expression and SIRT1 activity [31]. Furthermore, as SIRT1 and PARP2 are
both NAD+-dependent enzymes that compete for the same NAD+ pool [2,5,6,37,75,87], the genetic
Cells 2020, 9, 380 16 of 21
inactivation of PARP2 can induce NAD+ levels and contribute to the induction of SIRT1 [37]. These
data link autophagy to cellular NAD+ homeostasis.
What physiological or pathological changes can influence PARP2 expression when the regulatory
effects of PARP2 may impact on autophagy? To date, the effects modulating PARP2 expression had
not been assessed in detail. Nevertheless, there are studies in the literature where the pathology
discussed is related to autophagy induction. Sun and colleagues [66] showed that serum deprivation,
a known inducer of autophagy, can decrease PARP2 expression. Furthermore, there are lipid species
and drugs that can modulate PARP2 expression [63]. Finally, PARP2 depletion is partially protective
in neurodegenerative diseases that are related to the deregulation of autophagy [88,89]. As a logical
continuation to this list, the silencing of PARP2 supported the differentiation of myoblasts to myofibers,
at least in part, through the modulation of autophagy and, in line with that, the depletion of PARP2
was protective against cancer cachexia and muscle wasting [56].
PARP2 represents a novel link between DNA repair and autophagy machinery [90,91]. Silencing of
PARP2 blocks the processing of the autophagic vesicles, suggesting its involvement in the progression
of autophagy. However, the exact molecular role of PARP2 remains to be elucidated.
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